|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1994-2-25
|
|
pubmed:abstractText |
Utilization of alpha-tumor necrosis factor (alpha-TNF) in clinical practice is limited by severe general side effects. Very promising results with low toxicity were reported with administration of alpha-TNF by isolation perfusion in extracorporeal circulation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
483-92
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8293417-Adult,
pubmed-meshheading:8293417-Aged,
pubmed-meshheading:8293417-Arm,
pubmed-meshheading:8293417-Carcinoma,
pubmed-meshheading:8293417-Chemotherapy, Cancer, Regional Perfusion,
pubmed-meshheading:8293417-Female,
pubmed-meshheading:8293417-Humans,
pubmed-meshheading:8293417-Interferon-gamma,
pubmed-meshheading:8293417-Leg,
pubmed-meshheading:8293417-Male,
pubmed-meshheading:8293417-Melanoma,
pubmed-meshheading:8293417-Melphalan,
pubmed-meshheading:8293417-Middle Aged,
pubmed-meshheading:8293417-Pilot Projects,
pubmed-meshheading:8293417-Sarcoma,
pubmed-meshheading:8293417-Skin Neoplasms,
pubmed-meshheading:8293417-Soft Tissue Neoplasms,
pubmed-meshheading:8293417-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan.
|
|
pubmed:affiliation |
Department of Surgical Oncology B, National Cancer Institute, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
